Skip to main content
logo
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
93.19
+3.26 (3.63%)
Oct 2, 2026, 4:00 PM EDT - Market closed

Spyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
8,2172,5421,36777528234
Market Cap Growth
726.48%85.99%76.31%2701.10%-88.19%-37.90%
Enterprise Value
7,0722,2121,108959-41127
Last Close Price
93.1932.7623.2821.5211.25118.75

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---874.9111.8812.50
PB Ratio
8.603.552.644.210.552.79
P/TBV Ratio
8.614.543.78-0.552.79

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
---1082.03-6.78

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
----0.090.07
Net Debt / Equity Ratio
-1.04-1.06-1.16-1.84-1.01-1.04
Net Debt / EBITDA Ratio
--2.902.900.611.37
Net Debt / FCF Ratio
5.484.473.833.400.641.62
Asset Turnover
---0.000.030.14
Quick Ratio
18.2312.9411.1610.613.834.66
Current Ratio
18.5313.2511.2610.684.254.91
Return on Equity (ROE)
-22.98%-25.17%-59.28%-289.17%-124.87%-58.81%
Return on Assets (ROA)
-19.81%-19.80%-27.43%-35.60%-58.53%-30.22%
Return on Capital Employed (ROCE)
-24.50%-30.50%-37.60%-38.00%-150.10%-73.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-1.83%-6.11%-15.22%-43.70%-302.87%-28.09%
FCF Yield
-2.54%-6.66%-11.52%-12.89%-289.74%-23.17%
Buyback Yield / Dilution
-31.80%-36.21%-581.85%-104.59%-28.19%-23.18%
SEC Filings: 10-K · 10-Q